AML1+/- HSCs show enhanced donor cell engraftment under conditions of competitive repopulation
. | Mean level of engraftment (%) . | . | . | |
|---|---|---|---|---|
| Time points . | AML1+/+ . | AML1+/- . | P . | |
| Week 4 | 5.372* | 8.212 | .0169† | |
| Week 8 | 5.608 | 9.314 | .0692 | |
| Week 12 | 4.855 | 10.713 | .0112 | |
| Week 16 | 4.419 | 10.706 | .0206 | |
| Week 20 | 4.913 | 11.481 | .0426 | |
| Week 24 | 4.589 | 11.796 | .0169 | |
. | Mean level of engraftment (%) . | . | . | |
|---|---|---|---|---|
| Time points . | AML1+/+ . | AML1+/- . | P . | |
| Week 4 | 5.372* | 8.212 | .0169† | |
| Week 8 | 5.608 | 9.314 | .0692 | |
| Week 12 | 4.855 | 10.713 | .0112 | |
| Week 16 | 4.419 | 10.706 | .0206 | |
| Week 20 | 4.913 | 11.481 | .0426 | |
| Week 24 | 4.589 | 11.796 | .0169 | |
The results are the average of 2 independent experiments. For each experiment, 5 to 6 mice per genotype received transplants using a ratio of 10:1 competitors to test cells. The level of engraftment in the peripheral blood (percentage of Ly5.2+ cells) was determined by FACS.
The statistical significance of the differences between the genotypes at each time point was assessed using an exact Wilcoxon test.